34 results
8-K
EX-10.1
VBIV
VBI Vaccines Inc.
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders
8-K
EX-99.1
qd9 uwapdcd365l29p
26 Oct 23
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
8:00am
8-K
EX-1.1
a1hbhpm
6 Jul 23
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
6:47pm
8-K
EX-10.1
ygbbdn6us16qz2gvh52
15 Sep 22
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
5:01pm
8-K
EX-1.1
08it8j 5dt1u43
3 Sep 21
Entry into a Material Definitive Agreement
8:53am
S-3ASR
EX-1.2
j0w8c6b6eab
31 Jul 20
Automatic shelf registration
4:58pm
8-K
EX-10.1
65zx577h 8m9e63d
27 May 20
VBI Vaccines Secures $50 Million Debt Financing From K2 HealthVentures
5:15pm
8-K
EX-1.1
ayd0zsiuhqu 1j38l
24 Apr 20
VBI Vaccines Announces Proposed Public Offering of Common Shares
6:16am
424B5
ft8e6vjd
20 Sep 19
Prospectus supplement for primary offering
5:28pm
8-K
EX-1.1
anql8df8 bkwwsn6hl7
20 Sep 19
VBI Vaccines Announces Proposed Public Offering of Common Shares
5:27pm